• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Cooperative Study Group A for Hematology - Developmental Therapeutics Review - Q4 2010 Product Image

Cooperative Study Group A for Hematology - Developmental Therapeutics Review - Q4 2010

  • ID: 1464330
  • December 2010
  • 35 pages
  • Global Markets Direct

Cooperative Study Group A for Hematology – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Cooperative Study Group A for Hematology - Developmental Therapeutics Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Cooperative Study Group A for Hematology - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cooperative Study Group A for Hematology human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of READ MORE >



List of Tables
List of Figures
Cooperative Study Group A for Hematology Snapshot
Key Information
Key Facts
Cooperative Study Group A for Hematology – Research and Development Overview
Key Therapeutic Areas
Cooperative Study Group A for Hematology – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Cooperative Study Group A for Hematology – Pipeline Products Glance
Cooperative Study Group A for Hematology – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Cooperative Study Group A for Hematology Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Cooperative Study Group A for Hematology – Drug Profiles
Cyclophosphamide + fludarabine + anti thymocyte globulin
Product Description
Mechanism of Action
R&D Progress
Cytarabine + Daunorubicin
Product Description
Mechanism of Action
R&D Progress
Flu-ATG
Product Description
Mechanism of Action
R&D Progress
busulfan + fludarabine
Product Description
Mechanism of Action
R&D Progress
Busulfex + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
CODOX-M/ IVAC
Product Description
Mechanism of Action
R&D Progress
Fludarabine + cytarabine
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Cytarabine + Idarubicin + G-CSF
Product Description
Mechanism of Action
R&D Progress
fludarabine + cytarabine + idarubicin + granulocyte colony-stimulating factor
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Melphalan + Allogeneic Non-Myeloablative Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
Cooperative Study Group A for Hematology – Pipeline Analysis
Cooperative Study Group A for Hematology – Pipeline Products by Therapeutic Class
Cooperative Study Group A for Hematology Pipeline Products By Target
Cooperative Study Group A for Hematology – Pipeline Products by Route of Administration
Cooperative Study Group A for Hematology – Pipeline Products by Molecule Type
Cooperative Study Group A for Hematology - Dormant Projects
Cooperative Study Group A for Hematology – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS